Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression Lucia Vráblová; Hana Klamová; Ivana Skoumalová; Jana Navrátilová; Romana Janská; Jan Grohmann; Milena Holzerová; Edgar Faber;

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT Bü¿ra Akdo¿an; Ali Turunç; Birol Güvenç;

Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies Tomasz Sacha; Katarzyna Krawczyk;